title: The NIMH-CATIE Schizophrenia Study: what did we learn?
authors.forename: Jeffrey A
authors.initials: JA
authors.lastname: Lieberman
authors.forename: T Scott
authors.initials: TS
authors.lastname: Stroup
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002908:Chronic Disease; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D057915:Drug Substitution; D006801:Humans; D040541:Marketing / Q000191:economics; D055118:Medication Adherence; D010352:Patient Dropouts; D010546:Perphenazine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D012565:Schizophrenic Psychology; D014481:United States
chemical_list: D014150:Antipsychotic Agents; D010546:Perphenazine